Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

NCTNCT05184374 (opens ClinicalTrials.gov in a new tab)Other idKY2021-674
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
20 participants (estimated)
Sponsor
Huashan Hospital · Other
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

China

Start
1 Jan 2022 (estimated)
Primary completion
30 Jun 2022 (estimated)
Completion
31 Dec 2022 (estimated)
First posted
11 Jan 2022
Last update posted
11 Jan 2022
Conditions
Hypogonadotropic Hypogonadism

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20222023
  1. N/A

    Efficacy of Prolonged GnRH Test in Male Adolescents With Postoperative HH

    NCT05184374

    est. 1 Jan 2022 to est. 31 Dec 2022

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The Hypogonadotropic Hypogonadism(HH) could be caused by sellar lesions, sellar surgery or sellar radiotherapy. The incidence of HH after sellar surgery was higher in men than in women, and the therapy of HH was insufficient. Gonadotropin-releasing hormone(GnRH) stimulation test is used to evaluate the function of pituitary-gonadal axis. GnRH can be used to diagnose and treat fertility disorders and other endocrine disorders caused by HH. After a single injection of GnRH, the patients with poor response of luteinizing hormone and follicle stimulating hormone need to take extended provocation test, which is conducive to the formulation of the following treatment. GnRH pump can pulse subcutaneous injection of gonadorelin, which can be used as the extended provocation test.

Interventions

  • GonadorelinDrug

Arms1

  • Experimental

    subcutaneous injection of gonadorelin is facilitated by GnRH pump

    After non-dose GnRH stimulation test on day 1, GnRH pump pulse subcutaneous injection of gonadorelin on the next day until one month.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. level of luteinizing hormone, follicle stimulating hormone and testosterone

    Time frame · 1 month

    Registry description

    after the GnRH pump of gonadorelin, the level of luteinizing hormone, follicle stimulating hormone and testosterone will be measured at 24h, 1, 2, 3 and 4 week

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
Male
Age
from 18 Years up to 50 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * patients with HH after surgery of the saddle area * sufficient therapy of the hypothalamic-pituitary-adrenal(HPA) and hypothalamic-pituitary-thyroid(HPT) axis Exclusion Criteria: * contradictions to gonadorelin * androgen-dependent prostate cancer * on the therapy of human chorionic gonadotropin(HCG) or testosterone

PepBank is a research reference. Talk to a doctor before you use any peptide.